Lucid Diagnostics (LUCD) Equity Ratio (2020 - 2026)

Lucid Diagnostics has reported Equity Ratio for 7 years, with the latest figure at 0.12 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 171.59% year-over-year to 0.12; the trailing twelve-month figure through Mar 2026 stood at 0.12 (up 171.59% YoY), and the FY2025 full-year result was 0.27, up 54.05% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.12, down from 0.27 in the prior quarter.
• The five-year high for Equity Ratio was 0.8 in Q2 2022, with the low at 0.16 in Q1 2025.
• Historically, Equity Ratio has averaged 0.36 across 5 years, with a median of 0.35 in 2023.
• Annual changes were most pronounced in 2024 — Equity Ratio jumped 307.11% — and 2025, when it plunged 144.18%.
• Lucid Diagnostics' Equity Ratio stood at 0.71 in 2022, then tumbled by 111.95% to 0.08 in 2023, then soared by 307.11% to 0.18 in 2024, then soared by 54.05% to 0.27 in 2025, then slumped by 56.59% to 0.12 in 2026.
• The last three Equity Ratio figures came in at 0.12 (Q1 2026), 0.27 (Q4 2025), and 0.49 (Q3 2025), per Business Quant data.